Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 6/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL469674 | 0.84 | SLC5A2 (0.49) | SLC5A2SMN1; SMN2POLBSLC5A1LMNA | |
| SCHEMBL462685 | 0.79 | SLC5A2 (0.53) | SLC5A2SMN1; SMN2MAPK1LMNAL3MBTL1 | |
| SCHEMBL152867 | 0.79 | SLC5A2 (0.46) | SLC5A2SMN1; SMN2POLBSLC5A1L3MBTL1 | |
| SCHEMBL462800 | 0.77 | SLC5A2 (0.37) | SLC5A2 | |
| SCHEMBL454666 | 0.75 | SLC5A2 (0.47) | SLC5A2SLC5A1MAPT | |
| SCHEMBL14449300 | 0.72 | POLB (0.59) | P2RX3SMN1; SMN2MAPK1POLBLMNA | |
| SCHEMBL469637 | 0.69 | SLC5A2 (0.35) | SLC5A2MAPT | |
| SCHEMBL18715512 | 0.68 | POLB (0.50) | P2RX3SMN1; SMN2MAPK1POLBLMNA | |
| SCHEMBL460839 | 0.67 | SLC5A2 (0.48) | SLC5A2POLBLMNAL3MBTL1ALDH1A1 | |
| SCHEMBL8635590 | 0.66 | POLB (0.45) | SLC5A2MAPK1POLBSLC5A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006187-B2 | Thiophene derivative as SGLT2 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2015-04-14 | — | — | US | disclosed |
| US-9006187-B2 | Thiophene derivative as SGLT2 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2015-04-14 | — | — | US | disclosed |
| US-9006187-B2 | Thiophene derivative as SGLT2 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2015-04-14 | — | — | US | disclosed |
| US-20130172278-A1 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2013-07-04 | — | — | US | disclosed |
| US-20130172278-A1 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2013-07-04 | — | — | US | disclosed |
| US-20130172278-A1 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2013-07-04 | — | — | US | disclosed |
| WO-2012033390-A2 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012033390-A2 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172278-A1 | NOVEL THIOPHENE DERIVATIVE AS SGLT2 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885P2RX3 1311/4885SMN1; SMN2 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.